This study investigates sacituzumab govitecan, a Trop-2–targeted drug, showing 28% response in recurrent endometrial cancer and manageable safety in heavily pretreated patients.
This study investigates financial conflicts of interest in the US cancer ecosystem, showing over 50% prevalence across clinical trials, oncologists, and decision-making organizations.
This study investigates how genetic background affects cancer evolution, showing that inherited genetic differences shape tumor growth, driver mutations, and genome instability in mice, with implications for personalized cancer research.
This study investigates combining osimertinib and gefitinib in advanced lung cancer with EGFR C797S mutation, showing modest benefits but highlighting tumor resistance and limited efficacy.